Angle Regulatory News (AGL)



Regulatory News for Angle (AGL)


Share Price: 52.00Bid: 52.00Ask: 54.00Change: -1.00 (-1.89%)Faller - Angle
Spread: 2.00Spread as %: 3.85%Open: 53.00High: 53.76Low: 52.30Yesterday’s Close: 53.00





Director's share transfer

Thu, 27th Oct 2011 09:26

RNS Number : 9490Q
Angle PLC
27 October 2011
 

?

 

 

For immediate release

27 October 2011

 

ANGLE plc ("the Company")

 

Director's share transfer

 

ANGLE plc ("ANGLE"), which focuses on the commercialisation of technology, announces that it has received notification from Andrew Newland, Chief Executive of ANGLE, regarding the transfer of ordinary shares of 10p each ("Ordinary Shares") in the Company.

 

The Company was notified on 26 October 2011 that on the same day Andrew Newland transferred off market 69,204 ordinary shares of 10 pence each in the Company ("Ordinary Shares") to his personal pension fund at a price of 72.25 pence per share.

 

There is no change to Mr Newland's beneficial interest in the Company, which following this notification remains at 7,054,686 Ordinary Shares representing 19.65 per cent. of the Company's issued share capital.  

 

 

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 


Collins Stewart Europe Limited

Matt Goode

 

0207 523 8325

Buchanan

Lisa Baderoon

 

0207 466 5000

Scott Harris

Stephen Scott, Harry Dee

 

0207 653 0030

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLIFFTISLDFIL


Related Shares: Angle (AGL).




DateSourceHeadlineCategory
13-May-13 07:00RNSPARSORTIX CELL HARVESTINGCompany Announcement - General
07-May-13 07:00RNSParsortix Regulatory Approval UpdateCompany Announcement - General
28-Feb-13 07:00RNSParsortix Research Product LaunchCompany Announcement - General
15-Feb-13 10:56RNSDirector's share transferDirectors' Dealings
31-Jan-13 07:01RNSFundraising and Director's DealingsCompany Announcement - General
31-Jan-13 07:00RNSInterim ResultsResults and Trading Reports
16-Jan-13 07:00RNSNotification of Interim Results and WebcastCompany Announcement - General
15-Jan-13 07:00RNSAcolyte Biomedica SettlementCompany Announcement - General
14-Jan-13 07:00RNSParsortix Cell RecoveryCompany Announcement - General
07-Jan-13 07:00RNSAppointment of NEDExecutive Changes
18-Dec-12 07:00RNSParsortix Released to Research PartnersCompany Announcement - General
10-Dec-12 07:00RNSBUSINESS UPDATECompany Announcement - General
18-Oct-12 07:00RNSAppointment of Scientific AdvisersCompany Announcement - General
17-Oct-12 15:45RNSHolding(s) in the CompanyHolding(s) in Company
11-Oct-12 15:39RNSResult of 2012 Annual General MeetingResults and Trading Reports
03-Sep-12 07:00RNSIncreased FundraisingCompany Announcement - General
01-Aug-12 07:00RNSIncreased FundraisingCompany Announcement - General
26-Jul-12 07:01RNSFundraisingCompany Announcement - General
26-Jul-12 07:00RNSPreliminary ResultsResults and Trading Reports
24-Jul-12 07:00RNSNotice of Preliminary Results and Conference CallCompany Announcement - General
27-Jun-12 07:00RNSOffer Unconditional for Novocellus' Partner OrigioCompany Announcement - General
07-Jun-12 07:00RNSUpdate Re Novocellus' Partner ORIGIO A/SCompany Announcement - General
16-May-12 07:00RNSGeomerics Milestone PaymentCompany Announcement - General
30-Apr-12 07:00RNSParsortix Design BreakthroughCompany Announcement - General
26-Apr-12 07:00RNSLaunches New Corporate WebsiteCompany Announcement - General
23-Apr-12 07:00RNSParsortix Update for Breast CancerCompany Announcement - General
17-Apr-12 07:00RNSParsortix Validation for Ovarian CancerCompany Announcement - General
11-Apr-12 07:00RNSNovocellus Embryosure® Trial StartedCompany Announcement - General
15-Mar-12 07:00RNSParsortix Validation for Colon CancerCompany Announcement - General
07-Mar-12 08:00RNSHolding(s) in the CompanyHolding(s) in Company


Regulatory news is displayed end of day, each day at 19:00.
Sign up for Live Prices





Datafeed and UK data supplied by NETbuilder and Interactive Data. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.